MedTrace Logo

Radiofrequency Ablation of Pulmonary Tumors Response Evaluation

NCT00690703 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2008-06-05

No results posted yet for this study

Summary

The study hypothesis is that the radiofrequency (RF) ablation is a safe and effective treatment for malignant lung tumors.

Conditions

  • Non Small Cell Lung Cancer
  • Pulmonary Metastases

Interventions

DEVICE

RF ablation (Rita Medical Systems Model 1500x)

computed tomography-guided RF ablation with an expandable electrode needle

Sponsors & Collaborators

  • Angiodynamics, Inc.

    lead INDUSTRY

Principal Investigators

  • Riccardo Lencioni, MD · University of Pisa, Pisa, Italy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-07-31
Primary Completion
2006-12-31
Completion
2007-12-31

Countries

  • United States
  • Australia
  • Germany
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00690703 on ClinicalTrials.gov